» Articles » PMID: 30197510

Health Effects in COPD Smokers Who Switch to Electronic Cigarettes: a Retrospective-prospective 3-year Follow-up

Overview
Publisher Dove Medical Press
Specialty Pulmonary Medicine
Date 2018 Sep 11
PMID 30197510
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Health effects of electronic cigarette (EC) use in patients with chronic obstructive pulmonary disease (COPD) are largely unexplored.

Aim: We present findings from a long-term prospective assessment of respiratory parameters in a cohort of COPD patients who ceased or substantially reduced conventional cigarette use with ECs.

Methods: We prospectively re-evaluated COPD exacerbations, spirometric indices, subjective assessments (using the COPD Assessment Tool [CAT] scores), physical activity (measured by the 6-minute walk distance [6MWD]), and conventional cigarette use in EC users with COPD who were retrospectively assessed previously. Baseline measurements prior to switching to EC use were compared to follow-up visits at 12, 24, and 36 months. Age- and sex-matched regularly smoking COPD patients who were not using ECs were included as reference (control) group.

Results: Complete data were available from 44 patients. Compared to baseline in the EC-user group, there was a marked decline in the use of conventional cigarettes. Although there was no change in lung function, significant improvements in COPD exacerbation rates, CAT scores, and 6MWD were observed consistently in the EC user group over the 3-year period (<0.01). Similar findings were noted in COPD EC users who also smoked conventional cigarettes ("dual users").

Conclusion: The present study suggests that EC use may ameliorate objective and subjective COPD outcomes and that the benefits gained may persist long-term. EC use may reverse some of the harm resulting from tobacco smoking in COPD patients.

Citing Articles

Patterns of Use of e-Cigarettes and Their Respiratory Effects: A Critical Umbrella Review.

La Rosa G, Polosa R, OLeary R Tob Use Insights. 2025; 18:1179173X251325421.

PMID: 40078697 PMC: 11898095. DOI: 10.1177/1179173X251325421.


Prognostic value of composite inflammatory markers in patients with chronic obstructive pulmonary disease: A retrospective cohort study based on the MIMIC-IV database.

Liu X, Guo Y, Qi W PLoS One. 2025; 20(1):e0316390.

PMID: 39854548 PMC: 11761080. DOI: 10.1371/journal.pone.0316390.


A systematic review on risk factors and reasons for e-cigarette use in adolescents.

Villanueva-Blasco V, Belda-Ferri L, Vazquez-Martinez A Tob Induc Dis. 2025; 23.

PMID: 39822244 PMC: 11734163. DOI: 10.18332/tid/196679.


The effects of electronic cigarette use patterns on health-related symptom burden and quality of life: analysis of US prospective longitudinal cohort study data.

Cao Y, Zhang X, Fearon I, Li J, Chen X, Xiong Y Front Public Health. 2024; 12:1433678.

PMID: 39606086 PMC: 11600979. DOI: 10.3389/fpubh.2024.1433678.


Statistical analyses plan for "MAGnItude of cigarette substitutioN after initiation oF e-cigarettes and its ImpaCt on biomArkers of exposure and potenTial harm in dual users": MAGNIFICAT trial.

Belsey J, Weglarz J, Scherer M, Pluym N, Polosa R Heliyon. 2024; 10(21):e39695.

PMID: 39553606 PMC: 11565015. DOI: 10.1016/j.heliyon.2024.e39695.


References
1.
Caponnetto P, Campagna D, Cibella F, Morjaria J, Caruso M, Russo C . EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One. 2013; 8(6):e66317. PMC: 3691171. DOI: 10.1371/journal.pone.0066317. View

2.
Kon S, Canavan J, Jones S, M Nolan C, Clark A, Dickson M . Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014; 2(3):195-203. DOI: 10.1016/S2213-2600(14)70001-3. View

3.
Goniewicz M, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J . Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2013; 23(2):133-9. PMC: 4154473. DOI: 10.1136/tobaccocontrol-2012-050859. View

4.
MacNee W . Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2(4):258-66. PMC: 2713323. DOI: 10.1513/pats.200504-045SR. View

5.
Anthonisen N, Connett J, Kiley J, Altose M, Bailey W, Buist A . Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994; 272(19):1497-505. View